Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
Friday, February 28, 2014 12:45:25 PM
Well it just could be that;
NNVC therapeutic efficacy testing show remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits injected with 1000x viral loads required to ensure death. Standard industry protocols that measure efficacy by the time it takes to die for a treated mouse versus the control mice. Unprecedentedly, large percentages actually survive! Almost unheard of efficacy!
NNVC therapeutics shown to have similar efficacy in both injectable and oral forms.
NNVC therapeutics used in both forms show no apparent toxicity issues to date. Specific testing being currently planned and prepared for to verify.
From a comparative and historical perspective, stock dilution has been minimal demonstrating good stewardship and results per unit dollar achievement.
NNVC’s work good enough that is was awarded an orphan drug development designation in both the United States and Europe.
NNVC work good enough to now be an official candidate for a FDA Priority Review Voucher.
NNVC science independently confirmed by independent researchers in the area of pathogenesis and epidemiology of infectious diseases.
NNVC currently has sufficient funds to support 2 years of operations and into first human trials.
NNVC major insider purchases more shares from the open market in recent weeks.
NNVC therapeutics appear to be of a programmable design that can target nearly any type of virus in a matter of weeks!
Oh, and that is just to name a few possible reasons.
In the not too distant future, it just might be an NNVC nanoviricide that saves your life, or the life of a loved one. Do your own DD. Beware of misinformation. Read, study, think; a process that behooves us all.
Wishing all the best of good buys!
HS
Recent NNVC News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:30:36 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/15/2024 08:44:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM